Travere Therapeutics, Inc.
TVTX
Clasificación en acciones
#3577
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Precio por acción
$50.52
Última sincronización: 2026-10-19
Capitalización bursátil
$4.76B
Cambio (1 día)
1.85%
Cambio (1 año)
81.14%
País
US
Comercio Travere Therapeutics, Inc. (TVTX)
Categoría
Healthcare
Ganancias de Travere Therapeutics, Inc. (TVTX)
Ganancias en Jun 2026 TTM: $-67.07M
Secondo gli ultimi rapporti finanziari di Travere Therapeutics, Inc., gli utili attuali della società sono $-67.07M. Nel 2023, la società ha registrato un utile di $-376.11M, una disminución en comparación con agli utili del 2022, che erano di $-331.16M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Travere Therapeutics, Inc. desde 2009 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-67.07M | -79.07% |
| 2024 | $-320.51M | -14.78% |
| 2023 | $-376.11M | 13.58% |
| 2022 | $-331.16M | 52.69% |
| 2021 | $-216.88M | 14.88% |
| 2020 | $-188.79M | 28.91% |
| 2019 | $-146.45M | 43.76% |
| 2018 | $-101.87M | 74.54% |
| 2017 | $-58.36M | 1.36% |
| 2016 | $-57.58M | -154.60% |
| 2015 | $105.47M | -193.01% |
| 2014 | $-113.40M | 236.02% |
| 2013 | $-33.75M | 11.22% |
| 2012 | $-30.34M | 166,022.06% |
| 2009 | $-18.27K | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
